New treatments for cancer that leverage our own immune systems to attack and destroy cancer cells provide long-term, durable therapeutic responses and, in an increasing number of cases, are achieving cures in patients suffering from life-threatening cancers.
These benefits for patients have been powered by recently developed therapeutic antibodies binding with high specificity to drug targets on immune and cancer cells.
We have nine immuno-oncology targets in our pipeline and will add to this as we explore four main therapeutic modalities:
- activation of anti-tumour NK- and T-cell activity;
- activation of macrophages to destroy cancer cells;
- depletion of immune-suppressor cells;
- increasing T-cell invasion into the tumour microenvironment.
Our approach and our portfolio are underpinned by our leading antibody discovery and development platforms and our strong partnerships that enhance target selection and our ability to deliver innovative new antibody-based therapies including next generation bi-specific antibodies or a new class of immunocytokines.
In particular, our technology platforms are especially effective in the discovery and development of antibodies for cancer immunotherapy for the following reasons:
- Kymab believes that its unique platform generates the largest antibody diversity of all available discovery systems, an important feature in the discovery of rare pharmacologically active molecules;
- Kymab's antibodies display long CDR3 loop lengths, which are essential in binding deeply buried epitopes of many drug targets;
- our discovery platform is able to create genetic knock-outs of selected target genes, vital in developing antibodies directed against a broad range of surface epitopes particularly on conserved targets.